Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
EsoBiotec Logo
EsoBiotec Growth Score
91
CB Rank
16284
Heat Score
59
EsoBiotec is a Belgian biotechnology business focused on the discovery of novel cancer therapies.
Acquired by
AstraZeneca Logo
AstraZeneca
Founded
obfuscation
PrivateSeries A Mont-saint-guibert, Brabant Wallon, Belgium11-50 www.esobiotec.com/
Biotechnology
Overview

EsoBiotec
Total Funding
obfuscation
Growth Score
91
Heat Score
59

Total Funding
obfuscation
obfuscation
Series A raised
obfuscation
Growth Score91
0 pts
in past quarter
Heat Score 59
1 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About EsoBiotec

CB Rank
16284
EsoBiotec is a Belgian biotechnology business focused on the discovery of novel cancer therapies.
Acquired by
AstraZeneca Logo
AstraZeneca
Founded
obfuscation
PrivateSeries A Mont-saint-guibert, Brabant Wallon, Belgium11-50 www.esobiotec.com/
Biotechnology

Funding Rounds

Series A
OBF
in
obfuscation
Seed
OBF
in
obfuscation
Grant
OBF
in
obfuscation

Key People

Details

Legal Name EsoBiotec BV
Operating Status Active
Company Type For Profit
Founders  Jean-Pierre Latere
About the Company
EsoBiotec is a Belgian biotechnology business focused on the discovery of novel cancer therapies.EsoBiotec's objective is to enable the human body to fight cancer by delivering 'in vivo' cell engineering to patients.
Predictions & Insights

Growth Insight

See this Growth Insight
EsoBiotec is
Lorem
 to be growing
Top Contributing Factors
Recently Raised Funding

Growth Prediction

See this Growth Prediction

Products & Services

ESO-T01
An in vivo BCMA CAR-T therapy candidate that reprograms T cells inside the patient to target multiple myeloma without lymphodepletion.
ENaBL Platform
A lentiviral vector platform that enables in vivo reprogramming of immune cells for off-the-shelf cell therapies.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 3
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Series A - EsoBiotec Logo
Series A - EsoBiotec
1
obfuscation
— Series A
obfuscation
Series A - EsoBiotec Logo
Series A - EsoBiotec
1
obfuscation
— Series A
obfuscation
Series A - EsoBiotec Logo
Series A - EsoBiotec
1
obfuscation
— Series A
obfuscation
Series A - EsoBiotec Logo
Series A - EsoBiotec
1
obfuscation
— Series A
obfuscation
Series A - EsoBiotec Logo
Series A - EsoBiotec
1
obfuscation
— Series A

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 3
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Series A - EsoBiotec Logo
Series A - EsoBiotec
1
obfuscation
— Series A
obfuscation
Series A - EsoBiotec Logo
Series A - EsoBiotec
1
obfuscation
— Series A
obfuscation
Series A - EsoBiotec Logo
Series A - EsoBiotec
1
obfuscation
— Series A
obfuscation
Series A - EsoBiotec Logo
Series A - EsoBiotec
1
obfuscation
— Series A
obfuscation
Series A - EsoBiotec Logo
Series A - EsoBiotec
1
obfuscation
— Series A

Investors

M&A Details

EsoBiotec was acquired by AstraZeneca for
obfuscation
on
obfuscation
. This deal was done in Cash.
Transaction Name 
EsoBiotec acquired by AstraZeneca Logo
EsoBiotec acquired by AstraZeneca
Acquired by 
AstraZeneca Logo
AstraZeneca
Announced Date 
obfuscation
Price 
obfuscation
Market Intelligence
People
View Profiles & Contacts
Headcount 11-50 Employee Profiles 1 Board Members and Advisors 3

Employee Profiles

Board Members and Advisors

News

News and Press

News•Jun 1, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 18, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 6, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Apr 29, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

920
-46.76%
 in past month

IT Spend

$173.5KThis year, EsoBiotec is projected to spend $173.5K on IT, according to Aberdeen.

Active Website Tech Count

5EsoBiotec is actively using 5 technologies for its website, according to BuiltWith. These include Google Font API, Font Awesome, and  Apache.

Total IP

1EsoBiotec has 1 registered patent in the 'Biochemistry; Beer; Spirits; Wine; Vinegar; Microbiology; Enzymology; Mutation Or Genetic Engineering' category, according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is EsoBiotec's headquarters? EsoBiotec is located in Mont-saint-guibert, Brabant Wallon, Belgium.Who invested in EsoBiotec? EsoBiotec has 6 investors including Invivo Capital Partners and  Sambrinvest.When was the last funding round for EsoBiotec? EsoBiotec closed its last funding round on
obfuscation
from a Series A round.Who are EsoBiotec's competitors? Alternatives and possible competitors to EsoBiotec may include OS Therapies, Kyverna Therapeutics, and  Calidi Biotherapeutics.How much funding has EsoBiotec raised to date? EsoBiotec has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(fe3140e 1)
|